PRESS RELEASE
November 14, 2024

Ziccum has appointed a nomination committee for the 2025 annual general meeting

The delegates have been appointed for the nomination committee in anticipation of Ziccum's 2025 annual general meeting ("AGM").

Ziccum's nomination committee for the annual general meeting 2025 has been appointed in accordance with the instructions for the nomination committee decided by the 2022 AGM.

The nomination committee consists of:
• Randy Rivera, Global Corporate Finance ("GCF")
• William Lithander, own mandate
• Göran Conradson, own mandate

Shareholders who wish to submit proposals to the nomination committee are welcome to contact the nomination committee via letter to Ziccum AB, Scheelevägen 22, 223 63 Lund, Sweden or via e-mail to agm@ziccum.com no later than 28 February 2025.

The 2025 annual general meeting will take place on Tuesday, 27 May 2025.

For more information about Ziccum, please contact:

Ann Gidner
CEO, Ziccum AB
Mail: gidner@ziccum.com
Mobile: +46 722140141

Jonas Ekblom
Chairman of the Board, Ziccum AB
Mail: ekblom@ziccum.com
Mobile: +46 736777540

Ziccum's Certified Adviser is
Vator Securities AB

About Ziccum

Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

Ziccum has appointed a nomination committee for the 2025 annual general meeting